Wells Fargo Reaffirms Their Buy Rating on AbbVie (ABBV)

Wells Fargo analyst Mohit Bansal maintained a Buy rating on AbbVie (ABBV – Research Report) yesterday and set a price target of $200.00. The company’s shares closed yesterday at $164.66.

According to TipRanks, Bansal is a 4-star analyst with an average return of 6.2% and a 52.94% success rate. Bansal covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Gilead Sciences, and Amgen.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for AbbVie with a $186.31 average price target, which is a 13.15% upside from current levels. In a report released on April 17, Barclays also assigned a Buy rating to the stock with a $195.00 price target.

ABBV market cap is currently $291.6B and has a P/E ratio of 60.57.

Based on the recent corporate insider activity of 53 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

AbbVie (ABBV) Company Description:

AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.